Drug Profile
Research programme: mTORC protein inhibitors - Intellikine/PKD Foundation
Latest Information Update: 03 Jun 2016
Price :
$50
*
At a glance
- Originator Intellikine
- Developer Intellikine; Takeda America Holdings
- Class Small molecules
- Mechanism of Action MTORC1 protein inhibitors; MTORC2 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Polycystic kidney disease
Most Recent Events
- 01 Jan 2012 Intellikine has been acquired and merged into Takeda America Holdings
- 11 Feb 2011 Preclinical trials in Polycystic kidney disease in USA (PO)